PerkinElmer Inc.
http://www.perkinelmer.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From PerkinElmer Inc.
Finance Watch: CARB-X Refills Coffers To Help Biopharmas Fight Resistant Bacteria
Private Company Edition: The global accelerator has new commitments from HHS and the Wellcome Trust. Also, Apollo buys into Sofinnova Partners with an up to €1bn investment, Castle Creek raised $124.6m in private funding this year in lieu of an IPO and Remix closed a $70m series B round.
Finance Watch: HilleVax, Belite Bio Launch First Two Biopharma IPOs In Q2
Also, Cytovia will go public via SPAC merger, Nkarta capitalized on its positive early NK cell therapy data with a $230m offering, and venture capital mega-rounds include $220m for Reify, $110m for Satellite Bio and $100m for OMass Therapeutics.
Keeping Track: Orphan Drugs Aplenty At US FDA, From Pyrukynd Approval To Adagrasib Standard Review
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Dealmaking Quarterly Statistics, Q3 2021
In the third quarter of 2021, medical device company M&A values reached $7.1bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $6.7bn.
Company Information
- Industry
- Research, Analytical Equipment & Supplies
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
-
Drug Discovery Technologies
- Genomics-Proteomics
-
Drug Discovery Technologies
- Other Names / Subsidiaries
-
- Analytica of Branford, Inc.
- Arnel Inc.
- BioLegend, Inc.
- Haoyuan Biotech Co. Ltd.
- Immunodiagnostic Systems Holdings PLC
- Opto Technology, Inc.
- Perten Instruments
- SYM-BIO Lifescience
- Tulip Diagnostics Private Limited
- Wallac Oy
- Vanadis Diagnostics, AB
- ViaCell
- Oxford Immunotec Global PLC